EntreMed Incorporated

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2, as well as new chemical entities associated with multi-kinase inhibition and HDAC inhibition, important targets in the treatment of oncology. Panzem® (2-methoxyestradiol or 2ME2), one of the Company’s two lead drug candidates, is currently being tested as a cancer therapeutic in five Phase 2 clinical trials, and has been granted U.S. Food and Drug Administration (FDA) Orphan Drug designation in three cancer indications, including glioblastoma multiforme (GBM), multiple myeloma, and ovarian cancer. MKC-1, a novel cell cycle inhibitor, is also in Phase 2 clinical trials for cancer. In May 2006, the Company commenced clinical studies with its third clinical-stage compound, ENMD-1198, in patients with advanced cancer. EntreMed is developing compounds that have broad therapeutic and commercial potential in oncology. In order to further advance its commercial objectives, EntreMed may seek strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas.

Contact Details: 9640 Medical Center Drive Rockville MD 20850 United States of America Tel: 240.864.2600 Fax: 240.864.2601 Email: ginnyd@entremed.com WWW: www.entremed.com/

Loading...

Recent Publications by EntreMed Incorporated:
Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs. The syntheses of 2-methoxyestradiol analogs with modifications at the...	29th September, 2009	EntreMed, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.	Bioorg Med Chem Lett. 2009 Nov 15;19(22):6459-62. Epub 2009 Sep 9. DOI Direct Link
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol. The syntheses of 21 analogs of 2-methoxyestradiol are presented, including...	29th September, 2009	EntreMed, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.	Bioorg Med Chem Lett. 2009 Nov 1;19(21):6241-4. Epub 2009 Aug 8. DOI Direct Link
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol. A novel series of 17-modified and 2,17-modified analogs of...	19th September, 2009	EntreMed, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.	Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. Epub 2009 Aug 21. DOI Direct Link
Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BACKGROUND: A critical component of disease progression in rheumatoid...	15th July, 2009	EntreMed,	BMC Musculoskelet Disord. 2009 May 1;10:46. DOI Direct Link
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Clinical studies using the microtubule-targeting agent 2-methoxyestradiol...	23rd August, 2008	EntreMed, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.	Mol Cancer Ther. 2008 Jun;7(6):1472-82. DOI Direct Link
→View more EntreMed Incorporated research publications.

BioNews Results for EntreMed Incorporated:
Today's Biggest Healthcare Gainers were ENMD, HLCS, CERS : by Penny Stock Pick Alert	Earthtimes.org:  Nov 13 2009 11:27AM Matching: entremed
Today's Biggest Healthcare Gainers were ENMD, HLCS, CERS : by Penny Stock Pick Alert	Earthtimes.org:  Nov 13 2009 11:26AM Matching: entremed
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference	Street Insider:  Nov 3 2009 12:52PM Matching: entremed
Data for EntreMeds ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference	Street Insider:  Nov 3 2009 12:27PM Matching: entremed
Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference	Forbes.com:  Nov 3 2009 12:54PM Matching: entremed
Promote your company here: BioNewsCast - Press Release Distribution	→View more EntreMed Incorporated news.

EntreMed Incorporated Clinical Trials:
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

EntreMed Incorporated Patents:
US Patent No.	Title
7498322	Antiangiogenic agents
6224902	Vaccines against sterols
6201104	Angiogenesis--inhibiting protein binding peptides and proteins and methods of use
6090617	Flow electroporation chamber with electrodes having a crystalline metal nitride coating
6074605	Flow electroporation chamber and method
→View more EntreMed Incorporated patents.

EntreMed Incorporated (ENMD) Financial information Links from Barchart
ENMD Quote from from Barchart.com
ENMD Chart from from Barchart.com
ENMD Profile from from Barchart.com
ENMD Opinion from from Barchart.com
→View more EntreMed Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 542 times since April 2007, the link to the organisation's website has been followed 75 times

Recent Search Terms used to find this page: entremed cancer drive | .

Search for more companies in Rockville

Search for more companies in MD

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for EntreMed Incorporated